The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. [electronic resource]
Producer: 20040323Description: 1569-77 p. digitalISSN:- 1042-8194
- Adenosine Diphosphate -- pharmacology
- Agammaglobulinaemia Tyrosine Kinase
- Amides -- pharmacology
- Animals
- Aspirin -- pharmacology
- Bleeding Time
- Catalytic Domain -- drug effects
- Collagen -- antagonists & inhibitors
- Drug Design
- Drug Evaluation, Preclinical
- Enzyme Inhibitors -- pharmacology
- Fibrinolytic Agents -- pharmacology
- Humans
- Janus Kinase 3
- Male
- Mice
- Mice, Inbred ICR
- Nitriles -- pharmacology
- Peptide Fragments -- pharmacology
- Platelet Activation -- drug effects
- Platelet Aggregation -- drug effects
- Platelet Aggregation Inhibitors -- pharmacology
- Platelet Membrane Glycoproteins -- drug effects
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pulmonary Embolism -- chemically induced
- Quinazolines -- pharmacology
- Receptors, Collagen -- drug effects
- Signal Transduction -- drug effects
- Thrombin -- pharmacology
- Thromboembolism -- chemically induced
- Thromboplastin -- toxicity
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.